Latest PD-L1 Stories
KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab,
OXFORD, England, April 16, 2015 /PRNewswire/ -- Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases,
Research Provides Potential Implications for Immunotherapy in Treatment of Gynecologic Cancers IRVING, Texas, March 29, 2015 /PRNewswire/ -- Caris Life Sciences® today announced the
CALGARY, March 26, 2015 /PRNewswire/ - Oncolytics Biotech(®) Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr.
SUNNYVALE, Calif., Feb. 27, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
Studies Find Potentially Predictive Biomarkers May Lead to Better Patient Outcomes, Bladder Cancer Treatment Options Extend Beyond Chemotherapy Milwaukee, WI
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
SAN DIEGO and BARCELONA, Spain, Nov.
Results Published in Cancer Epidemiology, Biomarkers & Prevention Demonstrate Utility of Caris Molecular Intelligence(TM) in Exploring Expression of Targetable Immune Proteins IRVING,
Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications PLEASANTON, Calif., Aug.
- A person in a secondary role, specifically the second most important character (after the protagonist).